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Adipose Mesenchymal Stromal Cells Isolated
From Type 2 Diabetic Patients Display Reduced
Fibrinolytic Activity
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Stem cells have been successfully used for the treatment of
critical limb ischemia (CLI). We conducted a clinical trial to
determine the feasibility of using autologous adipose-derived
mesenchymal stromal cells (AdMSCs) for the treatment of CLI.
Unexpectedly, two diabetic patients developed peripheral micro-
thrombosis. This adverse effect, which contrasts with the
reported antithrombotic properties of MSCs, may stem from the
diabetic environment that alters the ﬁbrinolytic activity of
AdMSCs, thereby increasing the probability of developing
thrombosis. Here, we conﬁrm this premise by demonstrating
that diabetic AdMSCs cultured in the presence of blood sera
expressed and released higher levels of plasminogen activator
inhibitor type 1, reduced levels of tissue plasminogen activator,
and lower D-dimer formation compared with nondiabetic AdMSCs.
Thus, to establish an appropriate cell therapy for diabetic patients,
we recommend including new preclinical safety tests, such as the
D-dimer and/or the tissue plasminogen activator-to-plasminogen
activator inhibitor type 1 ratio tests, to assess ﬁbrinolytic activity
of cells before implantation. Diabetes 62:4266–4269, 2013
We evaluated the safety and feasibility of usingautologous adipose-derived mesenchymalstromal cells (AdMSCs) for diabetic patients(ClinicalTrials.gov identiﬁer: NCT01257776).
Two diabetic patients developed distal microthrombosis
(DMT) that was controlled with aggressive antithrombotic
therapy. DMT was not detected when autologous AdMSCs
isolated from nondiabetic patients were used (Clin-
icalTrials.gov identiﬁer: NCT01745744) under identical
conditions, as reported in Table 1, or when autologous
bone marrow mononuclear cells (BMMNCs) were trans-
planted in diabetic patients with critical limb ischemia
(CLI) (ClinicalTrials.gov identiﬁer: NCT00872326) (1).
Development of AdMSCs-associated DMT has not been
previously reported and is in sharp contrast to the de-
scribed ﬁbrinolytic and antithrombogenic properties of
MSCs (2–4). This novel clinical observation raises the
possibility that the diabetic milieu of patients may alter the
functional properties of AdMSCs, thereby impairing se-
cretion of factors involved in ﬁbrinolysis. To validate this
premise, we evaluated whether AdMSCs isolated from
diabetic and nondiabetic patients and cultured in the
presence of healthy, diabetic, or nondiabetic blood sera
displayed differential expression levels of tissue plasmin-
ogen activator (tPA) and plasminogen activator inhibitor
type 1 (PAI-1), which may result in impaired ﬁbrinolytic
activity of AdMSCs derived from diabetic patients.
RESEARCH DESIGN AND METHODS
Blood samples. Human serum was from diabetic (hBS-D) and nondiabetic
(hBS-ND) patients with CLI, as well as from healthy volunteers (hBS). All
donors provided informed consent that was formerly approved by local and
regional medical research ethics committees.
AdMSCs procurement. AdMSCs were isolated from abdominal adipose tissue
biopsy specimens of diabetic (AdMSC-D) and nondiabetic (AdMSC-ND)
patients diagnosed with CLI and enrolled in two independent clinical trials
(EudraCT: 2008-001387-88 and EudraCT: 2009-013554-32), as previously de-
scribed (5). AdMSCs were cultured in Mesenchymal Stem Cell Basal Medium
(MSCBM, Lonza, Barcelona, Spain) complemented with growth supplements
(GS: MSCGM SingleQuots, Lonza), 100 units/mL penicillin-streptomycin, and
incubated at 37°C in a 20% O2 and 5% CO2 humidiﬁed atmosphere. Control
AdMSCs were purchased from ATCC.
Experimental setup. AdMSCs, AdMSC-D, and AdMSC-ND were plated at
a density of 5 3 104 cells/cm2. The following day, the media was replaced with
serum/GS-free MSCBM (Lonza) and 24 h after with MSCBM (Lonza) supple-
mented with GS, hBS, hBS-D, or hBS-ND. Supernatants were collected for
ELISA analysis and cells harvested for RNA extraction 24 h after sera addition.
Quantitative RT-PCR. cDNA was generated from 2 mg RNA using M-MLV
Reverse Transcriptase (Promega Biotech, Alcobendas, Spain). Primer
sequences for tPA and PAI-1 were designed using Primer3 Software (http://
frodo.wi.mit.edu/primer3/) and can be obtained upon request, whereas the
housekeeping gene primers for cyclophilin A (PPIA) and 60S acidic ribosomal
protein P0 (RPLP) were purchased from Tataabiocenter (Göteborg, Sweden).
QT-PCR was performed using a SensiFAST SYBR Lo-ROX Mix (Bioline
Reagents Ltd) and a 7500 Real-Time PCR System (Applied Biosystems). Three
distinct ampliﬁcations were performed for each transcript, and the CT assay
was applied to assess relative transcript levels of tPA and PAI-1.
tPA and PAI-1 secretion assay. Levels of total tPA (free and complexed) and
total PAI-1 (active complexed with tPA and latent inactive) secreted in the
media of the various experimental groups were quantiﬁed using precoated
ELISA plates (Bender MedSystems, Vienna, Austria) according to the manu-
facturer’s instructions.
Fibrin gel culture assay. Fibrin gels were prepared as previously described
(6). Subsequent to polymerization, 1 mL MSCBM without serum or with
GS, hBS, hBS-D, or hBS-ND was added to the clotted ﬁbrin gels. Medium
was collected 24 h later for D-dimer detection using the Blue D-Dimer Kit
(Teco, Neufahrn, Germany). Gels were ﬁxed in formalin and processed for
hematoxylin-eosin staining. The free-cell/area was quantiﬁed from four arbi-
trary images per slide per condition using ImageJ freeware.
Statistical analysis. Unless otherwise stated, data are represented as mean
values 6 SEM. Data were analyzed with one-way and two-way ANOVA tests.
The Tukey test was used for comparisons. Values of P # 0.05 were considered
statistically signiﬁcant.
RESULTS
We initially assessed the relative transcript levels of the
ﬁbrinolytic promoting factor tPA as well as the amount of
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secreted protein in isolated AdMSCs, -D, and -ND cultured
in the presence of GS (control), hBS, -D, and -ND. In the
control condition, all three cell populations exhibited simi-
lar tPA mRNA expression levels. However, when cultured
in media supplemented with blood sera (hBS, -D, and -ND),
tPA transcript levels and secreted protein levels were
signiﬁcantly lower in AdMSC-D compared with AdMSCs
and AdMSC-ND, suggesting that the addition of sera,
independent of its origin, inhibited tPA expression in
AdMSC-D (Fig. 1A and B).
We next evaluated whether levels of PAI-1 were also
altered in AdMSC-D compared with AdMSCs and AdMSC-
ND. Overexpression of PAI-1 has been shown to poten-
tially compromise normal ﬁbrin clearance mechanisms
and promote pathological ﬁbrin deposition and thrombotic
events (7,8). PAI-1 transcript levels were consistently
higher in AdMSC-D than in AdMSC-ND in all culture con-
ditions (Fig. 1C). Interestingly, AdMSCs exhibited a similar
PAI-1 expression pattern as AdMSC-D. Nonetheless, at the
protein levels, AdMSC-D secreted the highest quantity of
PAI-1, reaching maximum levels in the presence of hBS-D
(400 ng/mL), whereas AdMSCs and AdMSC-ND, indepen-
dent of serum condition, released ;150 to 200 ng/mL pro-
tein. In presence of GS (control), AdMSCs and AdMSC-D
both secreted similar low levels, whereas AdMSC-ND re-
leased barely detectable amounts of PAI-1 (Fig. 1D).
We next measured the ﬁbrinolytic activity of the various
AdMSCs. Cells were embedded into ﬁbrin clots to mimic
an ex vivo ﬁbrinolytic situation and cultured with GS or in
the presence of blood sera (hBS, -D, and -ND). Fibrin
degradation, as judged by a steady clearing zone sur-
rounding single cells, was signiﬁcantly hampered in
AdMSC-D compared with AdMSCs or AdMSC-ND. This
effect appeared to be independent of serum conditions
(Fig. 1E and F). In contrast, AdMSCs diplayed the highest
number of cell free/area, reaching maximum levels in the
presence of hBS-ND. Interestingly, AdMSC-ND cultured in
the presence of hBS-D produced signiﬁcantly less cell free/
area than cells cultured in hSB or hSB-ND (Fig. 1E and F).
To validate this observation, we measured levels of D-dimer,
a by-product of ﬁbrin degradation (Fig. 1G). Consistent with
lower cell free/area, AdMSC-D displayed blunted capacity
to generate D-dimers, independent of the serum (Fig. 1G).
Interestingly, D-dimer production from AdMSC-ND cul-
tured in hBS-D was as low as from AdMSC-D, suggesting
that blood derived from diabetic patients may also contain
other factors that inhibit ﬁbrinolysis without altering tPA
and PAI-1 levels (Fig. 1B and D).
DISCUSSION
Our results clearly demonstrate that diabetic-derived
AdMSCs have an altered phenotype indicating the existence
of a potential post-transcriptional mechanism that regulates
PAI-1 expression levels, typiﬁed by its increase resulting
in blunted ﬁbrinolytic activity. Exposing AdMSC-D to hBS
or hBS-ND did not alter this phenotype, indicating that
long-term ﬁbrinolytic modiﬁcations have potentially been
endowed that cannot be reverted under normal culture
conditions. The latter may therefore impart increased sus-
ceptibility to develop DMT in patients who receive trans-
plants of diabetic-derived AdMSCs. Interestingly, AdMSC-ND
cultured in hBS-D exhibited decreased ﬁbrinolytic activity
even though tPA and PAI-1 transcript levels and secreted
proteins were not signiﬁcantly altered by sera conditions.
These data suggest that blood-derived factors associated
with hyperglycemia most likely also contribute to decrease
ﬁbrinolytic activity. To our knowledge, this is the ﬁrst case
report on the adverse effect of using diabetic-derived
AdMSCs for cell therapy, which should be taken into account
TABLE 1
Clinical parameters and inclusion and exclusion criteria of diabetic and nondiabetic patients with CLI
Inclusion criteria Exclusion criteria
Written informed consent Malignancy and hematological
Age Cardiac disease risk factors
$18 and #75 years old (patients with diabetes) Severe heart failure (NYHA IV)
$18 and #89 years old (nondiabetic individuals) Malignant ventricular arrhythmias or unstable angina
Both sexes Stroke or myocardial infarction within the last 3 months
Population target Ejection fraction of the left ventricle less than 30%
Diabetes type 1 or 2 (HbA1c $6.5%; fasting blood
glucose 4–7 mmol/L)
Uncontrolled hypertension
Biochemical parameters
Ischemic nondiabetic patients Anemia (hemoglobin ,7.9 mg/dL)
Infrapopliteal atherosclerotic vascular disease
of severe grade with severe claudication or
Rutherford-Becker grade II–III or IV
Leukopenia
Thrombocytopenia (,100,000 platelets/mL)
Deep vein thrombosis in the previous 3 months
Ankle-brachial pressure index at rest ,0.8 Untreated proliferative retinopathy
Failed attempts of surgical or endovascular
revascularization (PTA/stents or bypass)
HIV, hepatitis B or hepatitis C virus
Other risk factors
Biochemical parameters BMI .40 kg/m2
Leukocytes $3,000/mL Predicted impossibility to obtain a biopsy
specimen providing 10 g adipose tissueNeutrophils $1,500/mL
Platelets $100,000/mL Patients who participated in a clinical trial within
the last 3 months before inclusion in this clinical trialAST/ALT #2.5 units/L
Creatinine #2.5 mg/dL Alcoholism
Women of childbearing potential must have negative
results on a pregnancy test
ALT, alanine aminotransferase; AST, aspartate aminotransferase; NYHA, New York Heart Association; PTA, percutaneous transluminal
angioplasty. A total of 60 patients with CLI (30 diabetic patients and 30 nondiabetic patients) fulﬁlled the same inclusion and exclusion
criteria and enrolled in the following clinical trials: ClinicalTrials.gov identiﬁers NCT01257776 (diabetic) and NCT01745744 (nondiabetic).
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FIG. 1. AdMSCs derived from diabetic patients display reduced and serum-independent ﬁbrinolytic activity. Expression analysis of tPA and PAI-1
I shown in AdMSCs isolated from AdMSCs, AdMSC-D, and AdMSC-ND and cultured in the presence of GS (control), hBS, hBS-D, and hBS-ND.
Detection of tPA mRNA expression (A). tPA protein release shows that the blood sera, independent of its origin, inhibited tPA expression in
AdMSC-D (B). PAI-1 mRNA expression (C). D: PAI-1 protein release. Note that AdMSC-D secreted the highest quantity of PAI-1. Relative mRNA
expression indicates the ratio between speciﬁc gene and housekeeping genes. Values are normalized to the expression in no stimulated AdMSCs,
which was arbitrarily set as 1. E: Hematoxylin and eosin staining shows AdMSCs-mediated lysis of the ﬁbrin gel. The cell is surrounded by
a clearing zone, except for AdMSC-D, which displays hampered capacity to degrade ﬁbrin gel independently of human blood serum used. Scale bars:
50 mm. F: Free cell/area quantiﬁcation from hematoxylin-eosin staining of arbitrary images. G: In quantiﬁcation of D-dimer production of AdMSCs
cultured in ﬁbrin clot, AdMSC-D displayed blunted capacity to generate D-dimers independently of serum used. Data are presented as mean
values 6 SEM (n = 4). Statistical signiﬁcance: *P £ 0.05, **P £ 0.01 for AdMSC-D compared with AdMSC-ND.
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for future clinical management. Thus, because MSCs are
widely used in cell therapy, we would recommend including
new preclinical safety tests, such as the D-dimer and/or tPA–
to–PAI-1 ratio tests, to assess ﬁbrinolytic activity of cells
before implantation. Such testing will aid in establishing an
appropriate therapy after implantation therapy tailor-made
for each individual patients.
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